Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

The University of Colorado Anschutz Medical Campus will lead a groundbreaking national clinical trial-supported by a $29 million grant from Octapharma-to evaluate whether early replacement of ...

(“Be Bio” or “the Company”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the first participant was treated with BE-101 in ...